Perspective
Volume 14:05, 2024

Journal of Bioengineering & Biomedical Science

ISSN: 2155-9538 Open Access

Biomedical Applications of Stem Cell Therapy in Treating Degenerative Diseases

Marc Batinac*
Department of Clinical Medical Sciences, University of Rijeka, Rijeka, Croatia

Introduction

Degenerative diseases, characterized by the progressive deterioration of specific tissues and organs, pose significant challenges to modern medicine. These conditions, which include Parkinson's disease, Alzheimer's disease, osteoarthritis, and spinal cord injuries, often lack curative treatments and heavily impact patients' quality of life. Traditional therapeutic approaches primarily focus on symptom management, offering limited scope for reversing tissue damage. Stem cell therapy has emerged as a groundbreaking biomedical intervention with the potential to address the root causes of degenerative diseases. By harnessing the unique properties of stem cells—self-renewal and the ability to differentiate into specialized cell types—scientists are developing innovative treatments aimed at regenerating damaged tissues, restoring lost functions, and halting disease progression. This article explores the biomedical applications of stem cell therapy in treating degenerative diseases, examining its principles, clinical successes, challenges, and future prospects.

Description

Understanding stem cells and their therapeutic potential

Stem cells are undifferentiated cells capable of dividing and differentiating into specialized cell types. They are broadly classified into Embryonic Stem Cells (ESCs) Derived from early-stage embryos, these cells are pluripotent, meaning they can differentiate into nearly any cell type. Adult Stem Cells (ASCs) Found in specific tissues like bone marrow and adipose tissue, these multipotent cells primarily regenerate tissues where they reside. Induced Pluripotent Stem Cells (iPSCs) Engineered by reprogramming adult cells to a pluripotent state, iPSCs offer a versatile and ethically acceptable alternative to ESCs. The therapeutic potential of stem cells lies in their ability to replace damaged cells, modulate the immune response, and release bioactive molecules that promote tissue repair [1].

Degenerative diseases and stem cell therapy

Neurological degenerative diseases, such as Parkinson's disease (PD), Alzheimer's disease (AD), and Amyotrophic Lateral Sclerosis (ALS), result from the progressive loss of neurons and their functions. In PD, the loss of dopamine-producing neurons in the substantia nigra leads to motor symptoms like tremors and rigidity. Stem cell therapy, particularly using iPSCs and neural stem cells, has shown promise in regenerating dopaminergic neurons. Clinical trials have demonstrated that transplanted neurons can restore dopamine levels, improving motor functions in PD patients. AD is characterized by the accumulation of amyloid plaques and neurofibrillary tangles, leading to cognitive decline. Stem cell therapies aim to replace lost neurons and deliver neurotrophic factors to protect existing cells. While still in experimental stages, ESC-derived neural progenitors have shown potential in preclinical models. Spinal Cord Injuries: Stem cell therapy for spinal cord injuries focuses on replacing damaged neurons, remyelinating axons, and reducing inflammation. Mesenchymal Stem Cells (MSCs) and iPSCs have been successfully used in animal models to restore partial motor function. Degenerative musculoskeletal conditions, such as Osteoarthritis (OA) and Intervertebral Disc Degeneration (IDD), involve the breakdown of cartilage and connective tissues. Osteoarthritis MSCs derived from bone marrow and adipose tissue are widely used to regenerate cartilage in OA. These cells secrete anti-inflammatory cytokines and extracellular matrix proteins, alleviating pain and improving joint function. Clinical studies have reported significant symptom relief and slowed disease progression in OA patients treated with MSCs. Intervertebral Disc Degeneration Disc degeneration is a major cause of chronic back pain. Stem cell therapy targets the regeneration of the nucleus pulposus, the inner core of intervertebral discs. MSCs injected into degenerated discs have shown potential in restoring disc height and mechanical function [2].

Cardiovascular degenerative diseases, such as Myocardial Infarction (MI) and heart failure, are leading causes of morbidity and mortality worldwide. Myocardial Infarction MI results in the irreversible loss of cardiomyocytes. Stem cell therapy aims to regenerate heart tissue and restore cardiac function. Studies using bone marrow-derived stem cells and iPSCs have shown improved cardiac function and reduced scar tissue in animal models and early-phase clinical trials. Heart Failure In advanced heart failure, stem cell-based strategies focus on improving myocardial regeneration and reducing fibrosis. ESC-derived cardiomyocytes and cardiac progenitor cells have demonstrated the potential to integrate into damaged myocardium and improve contractility. Type 1 Diabetes Mellitus (T1DM) is caused by the autoimmune destruction of insulin-producing beta cells in the pancreas. Stem cell therapy seeks to replace these cells, offering a potential cure. Beta Cell Regeneration iPSCs and ESCs have been differentiated into insulin-producing beta-like cells. Preclinical studies have shown that these cells can normalize blood glucose levels in diabetic models. Immune Modulation MSCs have been explored for their immunomodulatory properties, reducing autoimmune attacks on pancreatic beta cells [2].

Hematopoietic Stem Cell Transplantation (HSCT) is a well-established therapy for hematological degenerative conditions, such as leukemia, lymphoma, and aplastic anemia. HSCT replaces diseased bone marrow with healthy hematopoietic stem cells, enabling the regeneration of the blood and immune system. Gene Therapy Integration Combining HSCT with gene-editing technologies, such as CRISPR-Cas9, has expanded its applications to genetic disorders like sickle cell anemia and thalassemia. Degenerative eye diseases, including macular degeneration and retinal degeneration, can lead to vision loss. Stem cell therapy focuses on regenerating retinal cells and restoring vision. Macular Degeneration ESC-derived retinal pigment epithelial cells have shown promise in restoring vision in patients with age-related macular degeneration. Retinitis Pigmentosa iPSCs have been used to generate photoreceptor cells, offering hope for reversing blindness caused by retinal degeneration [3].

Challenges and limitations

Immune Rejection Allogeneic stem cell transplants risk immune rejection, necessitating immunosuppressive therapies. Ethical Concerns the use of ESCs raises ethical questions, leading to regulatory hurdles in many

***Address for Correspondence:** Marc Batinac, Department of Clinical Medical Sciences, University of Rijeka, Rijeka, Croatia, E-mail: BatMarc00@gmail.com*

Received: 02 October, 2024, Manuscript No. jbbs-24-156941; **Editor Assigned:** 05 October, 2024, PreQC No. P-156941; **Reviewed:** 18 October, 2024, QC No. Q-156941; **Revised:** 23 October, 2024, Manuscript No. R-156941; **Published:** 30 October, 2024, DOI: 10.37421/2155-9538.2024.14.438

countries. Tumorigenesis Pluripotent stem cells, if not properly differentiated, can form teratomas (tumors). Scalability producing large quantities of high-quality stem cells for clinical use is technically demanding and expensive. Variability in stem cell sources, preparation methods, and treatment protocols complicates reproducibility and regulatory approval.

Future directions

Gene Editing Techniques like CRISPR-Cas9 are being integrated with stem cell therapy to correct genetic mutations before transplantation. Personalized Medicine iPSCs derived from a patient's cells eliminate the risk of immune rejection and enable customized treatments. Bioprinting 3D bioprinting using stem cells is emerging as a method for creating complex tissues and organs. Synthetic biology engineering stem cells to produce specific therapeutic molecules or resist immune rejection is an exciting area of research. Clinical Translation Ongoing clinical trials aim to refine protocols, improve safety, and expand the therapeutic scope of stem cells [4,5].

Conclusion

Stem cell therapy represents a paradigm shift in the treatment of degenerative diseases, offering hope for regeneration and restoration where traditional treatments fall short. From neurological disorders to cardiovascular diseases, diabetes, and musculoskeletal conditions, the biomedical applications of stem cells are vast and transformative. Despite the challenges, advancements in stem cell research and allied technologies are steadily overcoming these hurdles, paving the way for safer, more effective therapies. The integration of gene editing, personalized medicine and bioprinting further enhances the potential of stem cell therapy to revolutionize healthcare. As research progresses and regulatory frameworks evolve, stem cell therapy is poised to become a cornerstone of regenerative medicine, improving the lives of millions suffering from degenerative diseases worldwide.

Acknowledgment

None.

Conflict of Interest

None.

References

1. Dominici, M. L. B. K., K. Le Blanc, I. Mueller and I. Slaper-Cortenbach, et al. "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement." *Cytotherapy* 8 (2006): 315-317.
2. Krych, Aaron J., Daniel BF Saris, Michael J. Stuart and Brittney Hacken. "Cartilage injury in the knee: assessment and treatment options." *J Am Acad Orthop Surg* 28 (2020): 914-922.
3. Richter, Dustin L., Robert C. Schenck Jr, Daniel C. Wascher and Gehron Treme. "Knee articular cartilage repair and restoration techniques: a review of the literature." *Sports health* 8 (2016): 153-160.
4. Lee, Andrew S., Chad Tang, Mahendra S. Rao and Irving L. Weissman, et al. "Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies." *Nat med* 19 (2013): 998-1004.
5. Dominici, M. L. B. K., K. Le Blanc, I. Mueller and I. Slaper-Cortenbach, et al. "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement." *Cytotherapy* 8 (2006): 315-317.

How to cite this article: Batinac, Marc. "Biomedical Applications of Stem Cell Therapy in Treating Degenerative Diseases." J Bioengineer & Biomedical Sci 14 (2024): 438.